Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Benchmark Reiterates Hold Rating on iQIYI (IQ) Following Q2 Earnings, Revenue Miss
• Benchmark Reiterates Buy Rating on Synopsys (SNPS) Amid 'Relatively Bearish' Sentiment Into Earnings